Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus MBVP versus MBVP in newly diagnosed primary CNS lymphoma
ACTRN12610000908033Phase 3Completed
- Sponsor
- HOVON
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate, teniposide, carmustine, prednisolone and 1 more in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Dec 2010; status: completed.
02
Drugs
rituximabmethotrexateteniposidecarmustineprednisolone
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ACTRN12610000908033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000908033.